Advanced Pancreatic Cancer Pipeline Therapeutics and Analysis, 2021
DelveInsight Business Research LLP
7 min read
ERYtech Pharma, GlaxoSmithKline, Galera Therapeutics, Propanc and several others key companies are set to transform the Advanced Pancreatic Cancer Pipeline landscape in the coming years.
Las Vegas, USA, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Advanced Pancreatic Cancer Pipeline Therapeutics and Analysis, 2021
ERYtech Pharma, GlaxoSmithKline, Galera Therapeutics, Propanc and several other key companies are set to transform the Advanced Pancreatic Cancer Pipeline landscape in the coming years.
DelveInsight’s, “Advanced Pancreatic Cancer Pipeline Insights, 2021” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Advanced Pancreatic Cancer pipeline landscape. It comprises Advanced Pancreatic Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Advanced Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights the inactive Advanced Pancreatic Cancer pipeline products.
ERYtech Pharma is developing a pipeline of product candidates for patients with high unmet medical needs. The company’s primary aim is on developing product candidates, which target the altered metabolism of cancer cells by stripping them of amino acids vital for their growth and survival.
In April 2020, ERYtech Pharma announced that the U.S. Food and Drug Administration (FDA) had permitted eryaspase Fast Track Designation to develop second-line treatment of patients with metastatic pancreatic cancer.
ERYtech Pharma in September 2018, initiated a randomized, phase III study of Eryaspase in combination with chemotherapy versus chemotherapy alone as 2nd-line treatment of patients with Pancreatic Adenocarcinoma. The trial is expected to be completed in April 2021.
In March 2017, ERYtech Pharma announced positive topline results from its Phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA), combined with chemotherapy for the treatment of second-line metastatic pancreatic cancer.
Eryaspase is in phase III clinical development to treat second-line pancreatic cancer and in phase II for the treatment of first-line triple-negative breast cancer.
In October 2020, Galera Therapeutics announced interim data from Pilot Phase 1 /2 trial of GC1149 in combination with stereotactic body radiation therapy showed improved overall survival in patients with locally advanced pancreatic cancer.
Approximately 100+ key companies such as ERYtech Pharma, GSK, Galera Therapeutics, Propanc, and many others are developing Advanced Pancreatic Cancer therapies.
Advanced Pancreatic Cancer means cancer has spread from where it started or has come back sometime after treatment (recurrence). Advanced Pancreatic Cancer Treatment is usually chemotherapy. Chemotherapy travels via the bloodstream to reach cancer cells, which are in many places throughout the body. This treatment may reduce the tumors or impede their growth and may benefit patients to live longer.
The lead product candidate, Eryaspase consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in phase III clinical development for the second-line pancreatic cancer treatment and in phase II for first-line triple-negative breast cancer treatment. Leveraging its proprietary ERYCAPS platform that utilises a novel technology to encapsulate drug substances inside red blood cells, ERYtech develops a pipeline of product candidates for patients with high unmet medical needs.
What are the current options for Advanced Pancreatic Cancer treatment?
How many companies are developing therapies for the treatment of Advanced Pancreatic Cancer?
How many Advanced Pancreatic Cancer emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Advanced Pancreatic Cancer?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Advanced Pancreatic Cancer market?
Which are the dormant and discontinued products and the reasons for the same?
What is the unmet need for current therapies for the treatment of Advanced Pancreatic Cancer?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Advanced Pancreatic Cancer therapies?
What are the key designations that have been granted for the emerging therapies for Advanced Pancreatic Cancer?
How many patents are granted and pending for the emerging therapies for the treatment of Advanced Pancreatic Cancer?
DelveInsight's Advanced Pancreatic Cancer Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's Advanced Pancreatic Cancer - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Advanced Pancreatic Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's Metastatic Castration-Resistant Prostate cancer - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s ‘Neoantigen-based Personalized Cancer therapeutic Vaccines-Competitive Landscape and Market Forecast—by 2035’ report delivers an in-depth understanding of the Neoantigen-based Personalized Cancer therapeutic Vaccines.
DelveInsight's Hepatic Encephalopathy - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s ‘ICONS-Next Generation Immunotherapy- Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the ICOS as well as the market trends of ICOS-Next Generation Immunotherapy.
DelveInsight's ATCL Market report 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market trends in 7MM.
DelveInsight's "Goitre Market Insight Report 2030" delivers an in-depth comprehension of historical and forecasted epidemiology, market share, trends and forecast in the 7MM.
DelveInsight's Clostridium Difficile Infections Market Insights, Epidemiology and Forecast 2030 report provides a detailed overview of the disease & understanding of forecasted epidemiology.
About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
